CDC25B and neoplasm: To broaden our research in novel anti-tumor lead compounds, we selected Cell Division Cycle 25B (CDC25B), a specific tyrosine phosphatase [12], and epidermal growth factor receptor (EGFR), an Erb family receptor [13], as screening targets.